Literature DB >> 22860172

ACS chemical neuroscience molecule spotlight on contrave.

Susan L Mercer1.   

Abstract

Contrave is an investigational fixed-dose combination drug of naltrexone and bupropion currently in Phase III clinical trials for the treatment of obesity. Orexigen Therapeutics, Inc. has demonstrated efficacy of their product and is currently addressing FDA safety concerns and deciding future actions.

Entities:  

Keywords:  Contrave; bupropion; naltrexone; obesity; weight-loss

Mesh：

Substances：

Year:  2011        PMID： 22860172      PMCID： PMC3369782          DOI： 10.1021/cn200076y

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN： 1948-7193            Impact factor:   4.418


  4 in total

1.  Integration of NPY, AGRP, and melanocortin signals in the hypothalamic paraventricular nucleus: evidence of a cellular basis for the adipostat.

Authors:  M A Cowley; N Pronchuk; W Fan; D M Dinulescu; W F Colmers; R D Cone
Journal:  Neuron       Date:  1999-09       Impact factor: 17.173

2.  Opioids hyperpolarize beta-endorphin neurons via mu-receptor activation of a potassium conductance.

Authors:  M J Kelly; M D Loose; O K Ronnekleiv
Journal:  Neuroendocrinology       Date:  1990-09       Impact factor: 4.914

3.  Prevalence and trends in obesity among US adults, 1999-2008.

Authors:  Katherine M Flegal; Margaret D Carroll; Cynthia L Ogden; Lester R Curtin
Journal:  JAMA       Date:  2010-01-13       Impact factor: 56.272

4.  Hypothalamic proopiomelanocortin neurons are glucose responsive and express K(ATP) channels.

Authors:  Nurhadi Ibrahim; Martha A Bosch; James L Smart; Jian Qiu; Marcelo Rubinstein; Oline K Rønnekleiv; Malcolm J Low; Martin J Kelly
Journal:  Endocrinology       Date:  2003-04       Impact factor: 4.736
  4 in total
  4 in total

1.  Naltrexone/Bupropion ER (Contrave): Newly Approved Treatment Option for Chronic Weight Management in Obese Adults.

Authors:  Matthew M Sherman; Sinziana Ungureanu; Jose A Rey
Journal:  P T       Date:  2016-03

Review 2.  Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date.

Authors:  Assumpta Caixàs; Lara Albert; Ismael Capel; Mercedes Rigla
Journal:  Drug Des Devel Ther       Date:  2014-09-18       Impact factor: 4.162

Review 3.  Metabolic vs. hedonic obesity: a conceptual distinction and its clinical implications.

Authors:  Y-H Yu; J R Vasselli; Y Zhang; J I Mechanick; J Korner; R Peterli
Journal:  Obes Rev       Date:  2015-01-14       Impact factor: 9.213

Review 4.  Phentermine and topiramate for the management of obesity: a review.

Authors:  Gina Cosentino; Ariane O Conrad; Gabriel I Uwaifo
Journal:  Drug Des Devel Ther       Date:  2011-04-05       Impact factor: 4.162
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.